Using ligand-based virtualscreening and molecular dynamics simulations, Food and Drug Administration-approveddrugs have been screened as CHI3L1 inhibitors with the final goalsof being repurposed in MS and other inflammatory diseases, offeringpromising therapeutic approaches. The gene discussed is CHI3L1; the disease is myeloid sarcoma.